PLX - רווח לפני ריבית, מסים ופחת protalix.com

Protalix BioTherapeutics develops treatments for orphan diseases, utilizing plant-based protein synthesis to reduce costs. Production facilities in Israel ensure the stable output of FDA-approved drugs. The absolute EBITDA level helps assess financial dynamics, where 24.96 reflects the most recent value of the metric. The company is currently scaling the supply of biologics through partnerships with industry behemoths and developing new molecules.

This indicator measures net cash flow from operating activities, excluding the impact of financial and tax factors to assess the efficiency of the operating cycle. Stable bioreactor performance and scheduled maintenance of protein purification systems at Protalix BioTherapeutics (PLX) ensure the predictability of this flow; therefore, analyzing the history of operating profit in cash terms allows an investor to determine the sustainability of asset returns and avoid overpaying for the asset.